Mylan (MYL) is expected to report Q3 earnings on Thursday, October 29, before the market open, with a conference call scheduled for 10 am ET.
Analysts are looking for EPS of 27c on revenue of $1.23B. The consensus range is 24c-31c for EPS, and $1.18B-$1.28B for revenue, according to First Call. Positive drivers for the quarter include the company's growth prospects in Europe, and gains in new products like generic Depakote, Lamictal and Prilosec. Negatives for Mylan include a high debt load from acquisitions and the subsequent difficulties with integration.
On September 10, Goldman raised its price target on Mylan to $17 from $15. Goldman continues to like Mylan's shares based on its 2010 outlook and valuation. The firm rates shares a Buy.